Function: mean change in pain with movement from baseline on4‐point (0 to 3, 0 best function) Likert scale · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Global assessment of treatment success · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Health‐related quality of life (mental) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 2.34 [1.33, 4.14]
Studies not reported
Moderate
Total adverse events · acute gout
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 1.94 [1.36, 2.78]
Studies not reported
Moderate
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Swelling (mean) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Functional ability · people with systemic sclerosis
Autologous myeloablative selective HSCT may leads to higher functional ability – HAQ‐DIb Scale 0–3 with 0 representing no/mild… compared with cyclophosphamide (low certainty).
1 finding from 1 review
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
Autologous myeloablative selective HSCT probably leads to higher skin thickness – mRSS Scale 0–51 in which a higher number is worse… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
FVC · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in interstitial lung disease – FVC (% predicted) A lower percentage… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to lower event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Functional ability · people with systemic sclerosis
1 finding from 1 review
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
1 finding from 1 review
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found